Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1993-9-30
|
pubmed:abstractText |
The effect of intracerebroventricular (i.c.v.) injection of dynorphin A-(1-13) on the memory process was examined in mice, using spontaneous alternation performance related to working memory in a Y-maze. Dynorphin A-(1-13) (1, 3 and 10 micrograms) influenced neither spontaneous alternation performance nor total arm entries, which are considered to reflect locomotor activity. In contrast, dynorphin A-(1-13) (3 and 10 micrograms) significantly improved the impairment of spontaneously alternation performance induced by scopolamine (1 mg/kg s.c.). Simultaneously, the scopolamine-induced increase in total arm entries was markedly attenuated by dynorphin A-(1-13) (10 micrograms). The effect of dynorphin A-(1-13) (3 micrograms) on the scopolamine-induced impairment of spontaneous alternation was almost completely reversed by pretreatment with nor-binaltorphimine (4 micrograms i.c.v.), a kappa-selective opioid antagonist. These findings suggest that dynorphin A-(1-13) improves through the mediation of kappa-opioid receptors the scopolamine-induced impairment of spontaneous alternation performance associated with working memory.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Dynorphins,
http://linkedlifedata.com/resource/pubmed/chemical/Naltrexone,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Opioid, kappa,
http://linkedlifedata.com/resource/pubmed/chemical/Scopolamine Hydrobromide,
http://linkedlifedata.com/resource/pubmed/chemical/dynorphin (1-13),
http://linkedlifedata.com/resource/pubmed/chemical/norbinaltorphimine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0014-2999
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
4
|
pubmed:volume |
236
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
341-5
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8102969-Analysis of Variance,
pubmed-meshheading:8102969-Animals,
pubmed-meshheading:8102969-Drug Interactions,
pubmed-meshheading:8102969-Dynorphins,
pubmed-meshheading:8102969-Male,
pubmed-meshheading:8102969-Memory,
pubmed-meshheading:8102969-Mice,
pubmed-meshheading:8102969-Naltrexone,
pubmed-meshheading:8102969-Peptide Fragments,
pubmed-meshheading:8102969-Psychomotor Performance,
pubmed-meshheading:8102969-Receptors, Opioid, kappa,
pubmed-meshheading:8102969-Scopolamine Hydrobromide
|
pubmed:year |
1993
|
pubmed:articleTitle |
Dynorphin A-(1-13) markedly improves scopolamine-induced impairment of spontaneous alternation performance in mice.
|
pubmed:affiliation |
Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Meijo University, Nagoya, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|